AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial.
Andrey Alexandrovich Ivashchenko,Kirill A. Dmitriev,Natalia V. Vostokova,Valeria N Azarova,Andrew A. Blinow,Alina N. Egorova,Ivan G. Gordeev,Alexey P. Ilin,Ruben N. Karapetian,Dmitry V. Kravchenko,Nikita V. Lomakin,Elena A. Merkulova,Natalia A. Papazova,Elena P. Pavlikova,Nikolay Filippovich Savchuk,Elena N Simakina,Tagir A. Sitdekov,Elena A Smolyarchuk,Elena G. Tikhomolova,Elena V Yakubova,Alexandre V. Ivachtchenko +20 more
TLDR
In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within 4 days, and was safe and well-tolerated.Citations
More filters
Journal ArticleDOI
Drug treatments for covid-19: living systematic review and network meta-analysis.
Reed A C Siemieniuk,Jessica J Bartoszko,Long Ge,Dena Zeraatkar,Ariel Izcovich,Elena Kum,Hector Pardo-Hernandez,Anila Qasim,Juan Pablo Diaz Martinez,Bram Rochwerg,Francois Lamontagne,Mi Ah Han,Qin Liu,Arnav Agarwal,Arnav Agarwal,Thomas Agoritsas,Derek K. Chu,Rachel Couban,Ellen Cusano,Andrea Darzi,Tahira Devji,Bo Fang,Carmen Fang,Signe Flottorp,Signe Flottorp,Farid Foroutan,Farid Foroutan,Maryam Ghadimi,Diane Heels-Ansdell,Kimia Honarmand,Liangying Hou,Xiaorong Hou,Quazi Ibrahim,Assem M. Khamis,Bonnie Lam,Mark Loeb,Maura Marcucci,Shelley McLeod,Sharhzad Motaghi,Srinivas Murthy,Reem A. Mustafa,Reem A. Mustafa,John Neary,Gabriel Rada,Irbaz Bin Riaz,Behnam Sadeghirad,Nigar Sekercioglu,Lulu Sheng,Ashwini Sreekanta,Charlotte Switzer,Britta Tendal,Lehana Thabane,George Tomlinson,Tari Turner,Per Olav Vandvik,Robin W.M. Vernooij,Andrés Viteri-García,Ying Wang,Liang Yao,Zhikang Ye,Gordon H Guyatt,Romina Brignardello-Petersen +61 more
TL;DR: Glucocorticoids probably reduce mortality and mechanical ventilation in patients with covid-19 compared with standard care and the effectiveness of most interventions is uncertain because most of the randomised controlled trials so far have been small and have important study limitations.
Journal ArticleDOI
Efficacy and Safety of Favipiravir, an Oral RNA-Dependent RNA Polymerase Inhibitor, in Mild-to-Moderate COVID-19: A Randomized, Comparative, Open-Label, Multicenter, Phase 3 Clinical Trial.
Zarir F. Udwadia,Pawan Singh,Hanmant Barkate,Saiprasad Patil,Shabbir Rangwala,Amol Pendse,Jatin Kadam,Wen Wu,Cynthia F. Caracta,Monika Tandon +9 more
TL;DR: Significant improvement in time to clinical cure suggests favipiravir may be beneficial in mild-to-moderate COVID-19, and statistical significance on the primary endpoint was confounded by limitations of the RT-PCR assay.
Journal ArticleDOI
A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19.
Yohei Doi,Masaya Hibino,Ryota Hase,Michiko Yamamoto,Yu Kasamatsu,Masahiro Hirose,Yoshikazu Mutoh,Yoshito Homma,Masaki Terada,Taku Ogawa,Fumihiro Kashizaki,Toshihiko Yokoyama,Hayato Koba,Hideki Kasahara,Kazuhisa Yokota,Hideaki Kato,Jun-ichi Yoshida,Toshiyuki Kita,Yasuyuki Kato,Tadashi Kamio,Nobuhiro Kodama,Yujiro Uchida,Nobuhiro Ikeda,Masahiro Shinoda,Atsushi Nakagawa,Hiroki Nakatsumi,Tomoya Horiguchi,Mitsunaga Iwata,Akifumi Matsuyama,Sumi Banno,Takenao Koseki,Mayumi Teramachi,Masami Miyata,Shigeru Tajima,Takahiro Maeki,Eri Nakayama,Satoshi Taniguchi,Chang Kweng Lim,Masayuki Saijo,Takumi Imai,Hisako Yoshida,Daijiro Kabata,Ayumi Shintani,Yukio Yuzawa,Masashi Kondo +44 more
TL;DR: Favipiravir did not significantly improve viral clearance as measured by reverse transcription-PCR by day 6 but was associated with numerical reduction in time to defervescence, and neither disease progression nor death occurred in any of the patients in either treatment group during the 28-day participation.
Journal ArticleDOI
The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials.
Soheil Hassanipour,Morteza Arab-Zozani,Bahman Amani,Forough Heidarzad,Mohammad Fathalipour,Rudolph Martinez-de-Hoyo +5 more
TL;DR: In this paper, a systematic review and meta-analysis of Favipiravir in the treatment of COVID-19 patients is presented. But, the results of the meta analysis revealed that the use of antiviral once the patient has symptoms is too late and this would explain their low efficacy in the clinical setting.
Journal ArticleDOI
Targeting TMPRSS2 and Cathepsin B/L Together May Be Synergistic Against SARS-CoV-2 Infection
TL;DR: It is found that drugs targeting the two pathways, although independent, could display strong synergy in blocking virus entry, and may help improve the deployability of drug combinations targeting host proteases required for the entry.
References
More filters
Journal ArticleDOI
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Manli Wang,Ruiyuan Cao,Leike Zhang,Xing-Lou Yang,Jia Liu,Mingyue Xu,Zhengli Shi,Zhihong Hu,Wu Zhong,Gengfu Xiao +9 more
TL;DR: This study evaluated the antiviral efficiency of five FAD-approved drugs including ribavirin, penciclovir, nitazoxanide, nafamostat, chloroquine and two well-known broad-spectrum antiviral drugs remdesivir and favipiravir against a clinical isolate of 2019-nCoV in vitro.
Journal ArticleDOI
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study.
Qingxian Cai,Minghui Yang,Dongjing Liu,Jun Chen,Dan Shu,Junxia Xia,Xuejiao Liao,Yuanbo Gu,Qiu’e Cai,Yang Yang,Chenguang Shen,Xiaohe Li,Ling Peng,Deliang Huang,Jing Zhang,Shurong Zhang,Fuxiang Wang,Jiaye Liu,Li Chen,Shuyan Chen,Zhaoqin Wang,Zheng Zhang,Ruiyuan Cao,Wu Zhong,Yingxia Liu,Lei Liu +25 more
TL;DR: In this open-label nonrandomized control study, FPV showed significantly better treatment effects on COVID-19 in terms of disease progression and viral clearance; if causal, these results should be important information for establishing standard treatment guidelines to combat the SARS-CoV-2 infection.
Journal ArticleDOI
Sample size tables for exact single‐stage phase II designs
TL;DR: Tables for single-phase II trials based on the exact binomial distribution are presented, and if the upper success rate is accepted, the lower success rate may be included in the final confidence interval for the proportion being estimated.
Journal ArticleDOI
A review of the safety of favipiravir - a potential treatment in the COVID-19 pandemic?
TL;DR: Favipiravir demonstrates a favourable safety profile regarding total and serious AEs, however, safety concerns remain: hyperuricaemia, teratogenicity and QTc prolongation have not yet been adequately studied.
Journal ArticleDOI
Available Evidence and Ongoing Clinical Trials of Remdesivir: Could It Be a Promising Therapeutic Option for COVID-19?
TL;DR: This review is specifically aimed to summarize the available evidence and ongoing clinical trials of remdesivir as a potential therapeutic option for COVID-19, an investigational drug having broad spectrum antiviral activity with its target RNA dependent RNA polymerase.
Related Papers (5)
Remdesivir for the Treatment of Covid-19 - Final Report.
John H. Beigel,Kay M. Tomashek,Lori E. Dodd,Aneesh K. Mehta,Barry S. Zingman,Andre C. Kalil,Elizabeth L. Hohmann,Helen Y. Chu,Annie Luetkemeyer,Susan Kline,Diego Lopez de Castilla,Robert W. Finberg,Kerry Dierberg,Victor F. Tapson,Lanny Hsieh,Thomas F. Patterson,Roger Paredes,Daniel A. Sweeney,William R. Short,Giota Touloumi,David Chien Lye,Norio Ohmagari,Myoung-don Oh,Guillermo M. Ruiz-Palacios,Thomas Benfield,Gerd Fätkenheuer,Mark G. Kortepeter,Robert L. Atmar,C. Buddy Creech,JD Lundgren,Abdel G. Babiker,Sarah Pett,James D. Neaton,Timothy Burgess,Tyler Bonnett,Michelle Green,Mat Makowski,Anu Osinusi,Seema U Nayak,H. Clifford Lane +39 more
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study.
Qingxian Cai,Minghui Yang,Dongjing Liu,Jun Chen,Dan Shu,Junxia Xia,Xuejiao Liao,Yuanbo Gu,Qiu’e Cai,Yang Yang,Chenguang Shen,Xiaohe Li,Ling Peng,Deliang Huang,Jing Zhang,Shurong Zhang,Fuxiang Wang,Jiaye Liu,Li Chen,Shuyan Chen,Zhaoqin Wang,Zheng Zhang,Ruiyuan Cao,Wu Zhong,Yingxia Liu,Lei Liu +25 more
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.
Bin Cao,Yeming Wang,Danning Wen,Wen Liu,Jingli Wang,Guohui Fan,Lianguo Ruan,Bin Song,Yanping Cai,Ming Wei,Xingwang Li,Jia'an Xia,Nanshan Chen,Jie Xiang,Ting Yu,Tao Bai,Xuelei Xie,Li Zhang,Caihong Li,Ye Yuan,Hua Chen,Huadong Li,Hanping Huang,Shengjing Tu,Fengyun Gong,Ying Liu,Yuan Wei,Chongya Dong,Fei Zhou,Xiaoying Gu,Jiuyang Xu,Zhibo Liu,Yi Zhang,Li Hui,Lianhan Shang,Ke Wang,Kunxia Li,Xia Zhou,Xuan Dong,Zhaohui Qu,Sixia Lu,Xujuan Hu,Shunan Ruan,Shanshan Luo,Jing Wu,Lu Peng,Fang Cheng,Lihong Pan,Jun Zou,Chunmin Jia,Juan Wang,Xia Liu,Shuzhen Wang,Xudong Wu,Qin Ge,Jing He,Haiyan Zhan,Fang Qiu,Li Guo,Chaolin Huang,Thomas Jaki,Frederick G. Hayden,Peter Horby,Dingyu Zhang,Chen Wang +64 more
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Yeming Wang,Yeming Wang,Dingyu Zhang,Guanhua Du,Ronghui Du,Jianping Zhao,Yang Jin,Shouzhi Fu,Ling Gao,Zhenshun Cheng,Qiaofa Lu,Yi Hu,Guangwei Luo,Ke Wang,Yang Lu,Huadong Li,Shuzhen Wang,Shunan Ruan,Chengqing Yang,Chunlin Mei,Yi Wang,Dan Ding,Feng Wu,Xin Tang,Xianzhi Ye,Yingchun Ye,Bing Liu,Jie Yang,Wen Yin,Aili Wang,Guohui Fan,Fei Zhou,Zhibo Liu,Xiaoying Gu,Jiuyang Xu,Lianhan Shang,Lianhan Shang,Yi Zhang,Lianjun Cao,Guo Tingting,Yan Wan,Hong Qin,Yushen Jiang,Thomas Jaki,Thomas Jaki,Frederick G. Hayden,Peter Horby,Bin Cao,Chen Wang +48 more